Physician profile
Ashrith Guha
NPI 1962609693
$60,800.01
in general payments reported to CMS, 2019-2025
30 companies · $986 in 2025
The $986 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,344 · 2020: $15K · 2021: $16K · 2022: $3,861 · 2023: $11K · 2024: $5,334 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,338 · Travel and Lodging: $4,418 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,025 · Honoraria: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,338.45 |
| Travel and Lodging | $4,418.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,025.00 |
| Honoraria | $2,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $21,843.74 | 2019-2024 | Uptravi, Opsumit |
| Abbott Laboratories | $15,902.12 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $9,838.86 | 2019-2021 | |
| One Lambda, INC. | $5,024.40 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $3,481.07 | 2021-2024 | Winrevair |
| Cvrx, INC. | $1,324.21 | 2021-2025 | Barostim Neo System |
| Abiomed | $814.96 | 2019-2025 | Impella |
| Impulse Dynamics (USA) INC. | $516.43 | 2021-2024 | Optimizer, Optimizer |
| Pfizer INC. | $304.21 | 2019-2025 | |
| Paragonix Technologies, INC. | $260.83 | 2024 | Baroguard, Lungguard, Liverguard |
| E.R. Squibb & Sons, L.L.C. | $255.94 | 2024-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $255.18 | 2019-2024 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.87 | 2022-2025 | Jardiance |
| Amgen INC. | $152.27 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $137.50 | 2019-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $112.89 | 2025 | Attruby |
| Scpharmaceuticals INC. | $85.41 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $47.27 | 2023-2024 | Inpefa |
| Madrigal Pharmaceuticals | $47.02 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $29.23 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.29 | 2025 | Lifevest |
| Tactile Systems Technology INC | $26.07 | 2022-2023 | Entre Plus, Flexitouch Plus |
| Astellas Pharma US INC | $23.90 | 2025 | Cresemba |
| Takeda Pharmaceuticals U.S.A., INC. | $23.88 | 2025 | Livtencity |
| Haemonetics Corporation | $23.60 | 2019 | |
| United Therapeutics Corporation | $20.24 | 2022 | |
| Sandoz INC. | $16.37 | 2019 | |
| Boston Scientific Corporation | $14.18 | 2020 | |
| Medtronic Vascular, INC. | $14.07 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashrith Guha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.